ERBB2 and breast carcinoma: It has been shown that the spontaneous conversion of HER2+ breast carcinoma cells to a cluster of differentiation 44, CD44+ HER2-basal/mesenchymal phenotype via EMT could lead to trastuzumab resistance [66].